Ketamine, originally developed as an anesthetic for medical and veterinary use, has seen a dramatic rise in non-medical consumption across Europe, and beyond. Once confined to hospital settings for pain management and anesthesia, the drug is now increasingly encountered in recreational contexts, raising alarms among public health officials. Its growing popularity stems partly from a misperception that because it is a licensed pharmaceutical, it carries lower risks than illicit substances—a belief experts warn is dangerously misleading.
The surge in ketamine use has been documented in multiple European countries, with Belgium reporting notable increases in seizures and emergency admissions linked to the substance. Authorities in Antwerp and West Flanders have intercepted significant quantities, including a half-kilogram find in a residential studio where the user reportedly still had traces of the powder visible. In another case, a couple was investigated for administering ketamine to their minor children, including a 13-year-old daughter, prompting intervention by youth protection services after the teenager sought medical facilitate.
These incidents reflect a broader trend: ketamine is no longer niche. Data from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) shows that ketamine seizures across the EU more than doubled between 2019 and 2022, reaching over 5.5 tonnes in the latter year. The Netherlands, Belgium, and France consistently rank among the top countries for ketamine seizures in Western Europe, suggesting established supply chains and growing demand.
Medical professionals emphasize that ketamine’s legal status does not equate to safety when used outside clinical supervision. Even as it has legitimate applications—such as treatment-resistant depression under strict protocols—its recreational use carries substantial risks. Short-term effects include confusion, elevated blood pressure, impaired motor function, and a dissociative state known colloquially as the “K-hole,” where users feel detached from their bodies and surroundings. This state increases vulnerability to accidents, assault, and self-harm.
Long-term or frequent use is associated with urinary tract complications, including ulcerative cystitis, which can lead to chronic pain and incontinence. Cognitive impairments, particularly in memory and executive function, have also been observed in regular users. Despite these dangers, ketamine continues to be perceived by some as a “softer” drug, partly due to its therapeutic image and the absence of the violent crime often linked to stimulants like cocaine or methamphetamine.
Public health responses are evolving. In Belgium, federal and regional authorities have increased monitoring of ketamine trends through the Early Warning System on Drugs, coordinated by the Scientific Institute of Public Health (WIV-ISP). Harm reduction initiatives, including drug testing services at festivals and in urban centers, now routinely screen for ketamine alongside other substances. These services aim to inform users about purity and potential contaminants, though they do not condone use.
Internationally, the United Nations Office on Drugs and Crime (UNODC) has noted ketamine’s transition from a primarily Asian market to a global phenomenon, with rising seizures reported in Oceania, Africa, and the Americas. The 2023 World Drug Report highlighted ketamine as one of the few substances showing consistent growth in both seizures and prevalence surveys, underscoring the necessitate for coordinated international monitoring.
Clinicians stress the importance of distinguishing between medical and non-medical use. Therapeutic ketamine, administered intravenously or via nasal spray in controlled settings, follows rigorous dosing guidelines and patient screening. Recreational use, by contrast, involves variable purity, unknown dosages, and often concurrent use of other substances—factors that significantly increase unpredictability and risk.
As ketamine’s presence in nightlife and private settings grows, experts call for clearer public messaging. Campaigns should emphasize that pharmaceutical origin does not imply safety in unregulated contexts, paralleling efforts made around prescription opioids. Education must target not only users but also peers, educators, and healthcare providers who may encounter signs of misuse.
For those seeking help, Belgium offers confidential support through drug helplines and outpatient treatment centers specializing in substance use disorders. General practitioners can provide referrals to mental health services or addiction specialists. In emergencies, immediate medical attention is crucial, particularly if someone exhibits prolonged dissociation, breathing difficulties, or signs of urinary distress after ketamine use.
The trajectory of ketamine use remains a pressing public health concern. While its medical value is undeniable in appropriate settings, the blurred line between therapeutic and recreational use demands vigilance. Ongoing surveillance, accessible harm reduction tools, and evidence-based education are essential to prevent further escalation.
As monitoring continues, the next official update on drug trends in Belgium is expected from the WIV-ISP in late 2026, when the annual report on psychoactive substances is scheduled for release. Until then, health authorities urge caution and informed decision-making.
We invite readers to share their perspectives or experiences related to substance awareness in the comments below. If you found this article informative, please consider sharing it to help spread accurate information about ketamine and its risks.